Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
ClinicalTrials.gov |
Last refreshed on:
|
19 October 2017 |
Main ID: |
NCT01927055 |
Date of registration:
|
16/08/2013 |
Prospective Registration:
|
Yes |
Primary sponsor: |
|
Public title:
|
A Clinical Study of Patients With Symptomatic NOH to Assess Sustained Effects of Droxidopa Therapy
|
Scientific title:
|
A Clinical Study of Patients With Symptomatic Neurogenic Orthostatic Hypotension to Assess Sustained Effects of Droxidopa Therapy |
Date of first enrolment:
|
November 2013 |
Target sample size:
|
61 |
Recruitment status: |
Terminated |
URL:
|
https://clinicaltrials.gov/show/NCT01927055 |
Study type:
|
Interventional |
Study design:
|
|
Phase:
|
Phase 3
|
|
Countries of recruitment
|
United States
| | | | | | | |
Contacts
|
Name:
|
Horacio Kaufmann, M.D. |
Address:
|
|
Telephone:
|
|
Email:
|
|
Affiliation:
|
NYU Langone Medical Center |
| | |
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- 1. 18 years and older and ambulatory (defined as able to walk at least 10 meters);
2. Clinical diagnosis of symptomatic orthostatic hypotension associated with Primary
Autonomic Failure (PD, MSA and PAF), Dopamine Beta Hydroxylase Deficiency;
3. At the Baseline visit (Visit 2), patients must demonstrate:
1. a score of at least 4 or greater on the Orthostatic Hypotension Symptom
Assessment (OHSA) Item #1;
2. a fall of at least 20 mmHg in their systolic blood pressure, within 3 minutes of
standing;
4. Provide written informed consent to participate in the study and understand
that they may withdraw their consent at any time without prejudice to their
future medical care;
Exclusion Criteria:
- 1. Score of 23 or lower on the mini-mental state examination (MMSE);
2. Concomitant use of vasoconstricting agents for the purpose of increasing blood
pressure;
1. Patients taking vasoconstricting agents such as ephedrine, dihydroergotamine, or
midodrine must stop taking these drugs at least 2 days or 5 half-lives (whichever
is longer) prior to their baseline visit (Visit 2) and throughout the duration of
the study;
3. Known or suspected alcohol or substance abuse within the past 12 months
(DSM-IV definition of alcohol or substance abuse);
4. Women who are pregnant or breastfeeding;
5. Women of child bearing potential (WOCP) who are not using at least one method
of contraception with their partner;
6. Male patients who are sexually active with a woman of child bearing potential
(WOCP) and not using at least one method of contraception;
7. Untreated closed angle glaucoma;
8. Diagnosis of hypertension that requires treatment with antihypertensive
medications (short-acting antihypertensives to treat nocturnal supine HTN are
allowed in this study) Any significant uncontrolled cardiac arrhythmia;
9. History of myocardial infarction, within the past 2 years;
10. Current unstable angina;
11. Congestive heart failure (NYHA Class 3 or 4);
12. History of cancer within the past 2 years other than a successfully treated,
non-metastatic cutaneous squamous cell or basal cell carcinoma or cervical cancer
in situ;
13. Gastrointestinal condition that may affect the absorption of study drug (e.g.
ulcerative colitis, gastric bypass);
14. Any major surgical procedure within 30 days prior to the Baseline visit
(Visit 2);
15. Previously treated with droxidopa within 30 days prior to the Baseline visit
(Visit 2);
16. Currently receiving any other investigational drug or have received an
investigational drug within 30 days prior to the Baseline visit (Visit 2);
17. Any condition or laboratory test result, which in the Investigator's
judgment, might result in an increased risk to the patient, or would affect their
participation in the study;
18. The Investigator has the ability to exclude a patient if for any reason they
feel the subject is not a good candidate for the study or will not be able to
follow study procedures.
Age minimum:
18 Years
Age maximum:
N/A
Gender:
All
|
Health Condition(s) or Problem(s) studied
|
Pure Autonomic Failure
|
Parkinson's Disease
|
Symptomatic Neurogenic Orthostatic Hypotension
|
Dopamine Beta Hydroxylase Deficiency
|
Multiple Systems Atrophy
|
Intervention(s)
|
Drug: Placebo
|
Drug: Droxidopa
|
Primary Outcome(s)
|
Change in Dizziness/ Lightheadedness/ Feeling Faint/ or Feeling Like You Might Blackout (OHSA Item 1)
[Time Frame: Change from Randomization to Week 1]
|
Source(s) of Monetary Support
|
Please refer to primary and secondary sponsors
|
|